GlaxoSmithKlineE Balance Sheet Health

Financial Health criteria checks 5/6

GlaxoSmithKlineE has a total shareholder equity of EGP1.9B and total debt of EGP518.6M, which brings its debt-to-equity ratio to 26.9%. Its total assets and total liabilities are EGP3.7B and EGP1.8B respectively. GlaxoSmithKlineE's EBIT is EGP582.9M making its interest coverage ratio -5.4. It has cash and short-term investments of EGP212.2M.

Key information

26.9%

Debt to equity ratio

ج.م518.64m

Debt

Interest coverage ratio-5.4x
Cashج.م212.21m
Equityج.م1.93b
Total liabilitiesج.م1.78b
Total assetsج.م3.71b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: BIOC's short term assets (EGP3.0B) exceed its short term liabilities (EGP1.7B).

Long Term Liabilities: BIOC's short term assets (EGP3.0B) exceed its long term liabilities (EGP82.5M).


Debt to Equity History and Analysis

Debt Level: BIOC's net debt to equity ratio (15.9%) is considered satisfactory.

Reducing Debt: BIOC's debt to equity ratio has increased from 16.4% to 26.9% over the past 5 years.

Debt Coverage: BIOC's debt is well covered by operating cash flow (23.3%).

Interest Coverage: BIOC earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies